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BACKGROUND: Globally, HIV (Human Immunodeficiency virus) prevalence is 
highest in Sub-Saharan Africa (WHO, 2015). Acute respiratory failure is the leading 
cause for admission and mortality in the ICU (Intensive Care Unit) for HIV infected 
patients (Sarkar and Rasheed, 2013). There appear to be no formal or standardized 
antimicrobial treatment guidelines for treating ARDS (Acute Respiratory Distress 
Syndrome) in patients with AIDS (Acquired Immunodeficiency Disease Syndrome). 
 
METHOD: This retrospective descriptive comparative study employed chart review 
in order to compare patient outcomes of HIV infected patients, admitted with an 
ARDS diagnosis to the ICU of a private hospital in Richards Bay (Kwazulu-Natal) 
between January and December 2013, following one of two treatment regimens: 1) 
pathogen-directed antimicrobial treatment or 2) broad spectrum antimicrobial 
treatment. Total population sampling was performed for this study and data was 
collected by means of data collection sheets. The included patients (n=30) were 
allocated to either one of the two treatment groups based on the antimicrobial 
treatment they received in the ICU (broad spectrum antimicrobial treatment, n = 12 
and pathogen-directed antimicrobial treatment, n = 18). The main outcome 
parameter for this study was survival rate to ICU discharge. The secondary outcome 
parameters were length of ICU stay and duration of antimicrobial therapy. The 
outcomes were compared both culture “blind” (without taking culture results into 
consideration) and cultures revealed (for patients with the same culture result). 
 
RESULTS: From the sample of 30 included patients there were 18 survivors (broad 
spectrum antimicrobial treatment, n = 7 and pathogen-directed antimicrobial 
treatment, n = 11). For the culture “blind” analysis, there was a significant difference 
in patient outcome for the main outcome parameter (p < α; α = 0.05) as well as for 
the secondary outcome parameters (H ≥ 3.84 (critical value); α = 0.05). 50% 
surviving patients in the broad spectrum treatment group were discharged by 43 
days in the ICU (median survival rate) and 50% surviving patients in the pathogen-
directed treatment group were discharged by 17 days in the ICU. The median length 
of ICU stay was 43 days for the broad spectrum treatment group and 17 days for 
the pathogen-directed group. The median duration of antimicrobial treatment was 
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43 days for the broad spectrum group and 17 days for the pathogen-directed group. 
For the cultures “revealed” analysis no formal statistical tests were performed due 
to small sample size (five surviving patients).  For the broad spectrum treatment 
group, 100% surviving patients were discharged by 7 days in the ICU and for the 
pathogen-directed group, 100% surviving patients were discharged by 32 days in 
the ICU. The median length of ICU stay was 11 days for the broad spectrum group 
and 21 days for the pathogen-directed group. The median duration of antimicrobial 
treatment was 11 days for the broad spectrum group and 21 days for the pathogen-
directed group.  
 
CONCLUSION: This study revealed that there is a difference in patient outcome for 
the two antimicrobial treatments (broad spectrum and pathogen-directed). The 
culture “blind” analysis indicated that the pathogen-directed antimicrobial treatment 
is the treatment with the best outcome for AIDS patients with ARDS in the ICU, but 
the cultures “revealed´ analysis indicated to opposite, with broad spectrum 
antimicrobial treatment the treatment with the best patient outcome. In the latter 
case, however, no formal statistical tests were performed due to small sample size. 
The pathogen-directed approach will be the recommended treatment approach for 
treating ARDS among AIDS patients in the ICU for the draft in-house guideline. This 
approach resulted in better patient outcomes for the culture “blind” analysis. It is also 
the approach that theoretically limits the risk of antimicrobial resistance (van der 
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Acute Respiratory Distress Syndrome:  
 
Acute Respiratory Distress Syndrome (ARDS) is a serious reaction brought on by 
injury or acute infections of the lung, causing the leaking of more fluid than normal 
from the blood vessels into the alveoli (air sacs) and thus preventing the transport 
of oxygen from the atmosphere into the bloodstream. This leads to hypoxemia, 
multiple organ failure and eventually to death (American Thoracic Society, 2000).  
 
Patients with AIDS (Acquired Immune Deficiency Syndrome) frequently present with 
a wide spectrum of pulmonary complications resulting from a variety of opportunistic 
infections. Opportunistic infections of the lungs can result in ARDS. Acute 
respiratory failure is the main cause for intensive care unit (ICU) admissions for 
patients with HIV (Human Immunodeficiency Virus) and is associated with mortality 
rates as high as 50-68 percent (Sarkar and Rasheed, 2013).  
 
The most common infectious causes of acute respiratory failure in patients with 
AIDS are Pneumocystis jirovecii pneumonia and bacterial pneumonia (Sarkar and 
Rasheed, 2013 and Benito et al., 2012). In developed countries, the incidence for 
bacterial pneumonia is 60 percent and for Pneumocystis jirovecii pneumonia, 20 
percent (Benito et al., 2012). Streptococcus pneumoniae is most frequently the 
cause of bacterial pneumonia (incidence of 70 percent) in HIV infected patients, 
followed by Haemophilus influenza (10%), Staphylococcus aureus (9%) and 
Pseudomonas aeruginosa (5%) (Benito et al., 2012). Fungal infections include 
Histoplasma capsulatum, Crytococcus neoformans, Coccidioides immitis and 
Aspergillus. Other causative pathogens of respiratory failure include Mycobacteria, 
viruses such as Cytomegalovirus and Herpes Simplex virus and parasites like 






According to the American Thoracic Society (2000) management of ARDS consists 
of treating the underlying cause or illness, supportive care and prevention of 
complications. Supportive care is done by means of mechanical ventilation in order 
to deliver enough air to ensure adequate oxygen levels. The necessity for 
mechanical ventilation indicates severe ARDS. ARDS is considered severe if the 
ratio of partial pressure arterial oxygen and fraction of inspired oxygen is equal to or 
less than 100mmHg (BMJ Best Practice, 2016). In order to treat the underlying 
cause of ARDS appropriately, causative pathogen(s) need to be identified and the 
most appropriate antimicrobial(s) should be used to treat the patient. 
 
Most microbiological results only become available two to three days after cultures 
have been collected. Nonetheless, delayed treatment of ARDS – especially in 
combination with HIV – has potentially serious consequences, including increased 
mortality rates (Kollef, 2008 and Kumar et al., 2006). Therefore, it is common clinical 
practice to initiate empirical antimicrobial treatment as soon as a diagnosis of ARDS 
is established (Leekha et al., 2010). This approach can result in patients’ excessive 
exposure to (often inappropriate) antimicrobials. Unnecessary or inappropriate 
antimicrobial treatment is known to lead to adverse events and increased healthcare 
costs (Glowacki et al., 2003) as well as increased antimicrobial resistance (Leone 
and Martin, 2008). No literature was found indicating a specific empirical 
antimicrobial treatment strategy for AIDS patients with ARDS. 
 
Factors other than inappropriate antimicrobial treatment that can negatively affect 
the outcome for HIV infected patients with acute respiratory failure in the ICU 
include; mechanical ventilation, delayed ICU admission, increasing age, and the 
severity of illness (Sarkar, P. and Rasheed, HF. 2013). 
 
Antimicrobial resistance:  
 
Antimicrobial resistance is a pressing international concern (World Health 
Organization, 2013). The problem with antimicrobial resistance is that it reduces 
effectiveness of treatment. This leads to an increase in mortality rate, duration of 
treatment, healthcare costs and economic burden as more expensive therapies 
have to be used due to resistance to first-line treatment. The main contributing factor 
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to the emergence of antimicrobial resistance in hospitals is the excessive and 
prolonged antimicrobial treatment the patients receive. Another factor is the 
transmission of drug resistant pathogens among the large number of 
immunocompromised patients that are in close proximity to one another 
(MacDougall and Polk, 2005).   
 
Bacterial pneumonia is the main cause of acute respiratory failure in HIV infected 
patients, with Streptococcus pneumonia as the most frequently causative pathogen 
(Benito et al., 2012). The first fully penicillin-resistant strains of Streptococcus 
pneumonia were detected in South Africa as early as 1977 and the first multi-drug 
resistant strains occurred in 1978. Since then, the prevalence of resistance has 
increased worldwide, along with an increase in resistance to other antimicrobial 
classes. In 2004, a third of all the pneumococcal isolates studied in South Africa 
displayed multi-drug resistance (Crowther-Gibson et al., 2011). In many other 
countries the once fully penicillin susceptible strains of Streptococcus pneumonia 
have declined by almost half to even less than a quarter in some (Okeke et al., 
2005).  
 
Global and local HIV Statistics: 
 
According to the World Health Organization (2015), 36.9 million people were living 
with and 1.2 million have died from HIV in the year 2014. Sub-Saharan Africa is the 
worst affected by the epidemic, accounting for 70 percent of all new HIV infections 
worldwide. 
 
The global HIV prevalence rate for adults between 15-49 years of age was 0.8 
percent in 2014, with more than 10 percent of adults HIV positive in 9 countries. The 
highest adult HIV prevalence rate (4.8%) is in Sub-Saharan Africa, followed by the 
Caribbean (1.1%), Central Asia and Eastern Europe (0.9%), Latin America (0.4%), 
Central and Western Europe and North America (0.3%), the Pacific and Asia (0.2%) 
and North Africa and the Middle East with 0.1 percent. (Kaiser Family Foundation, 







Figure 1.1 Adult HIV prevalence (15-49 years) 2014. 
 
Globally, South Africa has the largest number of people (6.8 million) living with HIV 
(Kaiser Family Foundation, 2015). HIV prevalence is estimated to be 10.2 percent, 
with 16.8 percent among adults between 15-49 years of age (Statistics South Africa, 
2014). Of South Africa’s nine provinces, Kwazulu-Natal, site of this research, has 
the highest prevalence of HIV in South Africa: 16.9 percent in the general 
population, and 27.6 percent among adults aged 15-49 years (Van der Linde, 2013).  
 
1.2 PROBLEM STATEMENT 
 
Globally, HIV prevalence is highest in Sub-Saharan Africa (WHO, 2015). Acute 
respiratory failure is the leading cause for admission and mortality in the ICU for HIV 
infected patients (Sarkar and Rasheed, 2013). There is an urgent need to examine 
appropriate antimicrobial strategies for treating ARDS in patients with AIDS as there 
appear to be no formal or standardized treatment guidelines. Empirical antimicrobial 
treatment for critically ill ICU patients ranges from a pathogen-directed to a broad 
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spectrum approach (Leekha et al., 2010). The concern with a pathogen-directed 
approach is the possibility of undertreating the patient (File, 2015). In contrast, the 
anticipated complication associated with a broad spectrum approach is the potential 
contribution to the emergence of antimicrobial resistance (Leone and Martin, 2008).  
Antimicrobial resistance is as much a problem in South Africa as it is globally and 
can largely affect the clinical outcome for patients (Mendelson, 2012). Identifying the 
most appropriate antimicrobial treatment strategy is necessary in order to both 
ensure optimal clinical outcomes for the AIDS patient with ARDS in the ICU and limit 




There is no difference in patient outcomes when comparing broad spectrum 
antimicrobial and pathogen-directed treatment of ARDS among AIDS patients 
in the intensive care unit (ICU) setting. 
 
The main outcome parameter for this comparison was survival rate to ICU 
discharge. Secondary outcome parameters included total length of ICU stay and 
total duration of antimicrobial treatment. 
 
1.4 AIM AND OBJECTIVES 
 
The aim of this study was to retrospectively compare patient outcomes for pathogen-
directed with broad spectrum antimicrobial treatment in AIDS patients with ARDS 
admitted to a private hospital medical intensive care unit (ICU) in Kwazulu-Natal, 
South Africa.  
 
The objectives of this study were:  
1. To compare survival rate to ICU discharge of pathogen-directed with broad 
spectrum antimicrobial treatment over a 12 month period, January to 




2. To compare length of ICU stay of pathogen-directed with broad spectrum 
antimicrobial treatment over a 12 month period, January to December 2013, 
as measured by data collected from retrospective chart audits. 
3. To compare duration of pathogen-directed with broad spectrum antimicrobial 
treatment over a 12 month period, January to December 2013, as measured 
by data collected from retrospective chart audits. 
4. To formulate a set of in-house guidelines regarding antimicrobial treatment 
of ARDS in AIDS patients admitted to the medical ICU based on study 
results. 
 
1.5 STUDY DESIGN 
 
This study had a retrospective descriptive design that employed chart review in 
order to compare patient outcomes following two treatment regimens:  
1) pathogen-directed antimicrobial treatment and 2) broad spectrum antimicrobial 
treatment.  
 
1.6 DEFINITION OF TERMS 
 
AIDS (Acquired Immunodeficiency Disease Syndrome) – AIDS is known as the final 
stage of HIV infection.  An HIV infected person has AIDS if the CD4-count is below 
200 cells per cubic millilitre and/or if the individual manifests with one or more 
opportunistic infection (AIDSinfo, 2013). 
 
Antibiotic - Drug that kills or inhibits bacterial growth (MedicineNet, 2015). 
 
Antimicrobial drug – Drug that kills or inhibit the growth of microbes (MedicineNet, 
2015).  
Antimicrobial resistance – Antimicrobial resistance is resistance of a pathogen to an 
antimicrobial drug that was originally effective for treatment of infections caused by 




ARDS (Acute respiratory distress syndrome) - ARDS is part of a major systemic 
immune response brought on by injury or acute infection of the lung. The body’s 
response to injury or infection causes leaking of more fluid than normal from the 
blood vessels into the alveoli (air sacs); thus preventing efficient transport of oxygen 
through the bloodstream. This leads to hypoxemia, multiple organ failure and 
eventually to death (American Thoracic Society, 2000). ARDS is an extremely 
dangerous, life threatening condition. 
 
Broad spectrum antimicrobial treatment - An antimicrobial treatment regimen with 
the intent to target multiple pathogens with the potential to be (causally) associated 
with a patient’s presenting condition (Leekha et al., 2010). This is in contrast with a 
pathogen-directed treatment approach (see below).  
 
Empirical antimicrobial treatment – An antimicrobial treatment that is initiated based 
on experience and guided by clinical presentation, without data (culture results) to 
support its use (Leekha et al., 2010). 
 
HIV (Human Immunodeficiency Virus) – A retro virus that causes HIV infection by 
destroying or impairing the function of the immune system’s cells.  When the 
infection advances, the immune system becomes more fragile, and the infected 
person becomes more susceptible to infections (WHO, 2015).  
 
Pathogen-directed antimicrobial treatment – An antimicrobial treatment regimen 
aimed specifically at the most likely causative pathogen(s) associated with a 
patient’s presenting condition (Leekha et al., 2010). This is in contrast with a broad 
spectrum treatment approach (see above).  
 
Survival rate - Percentage of study participants alive for a certain period of time after 






CHAPER 2. LITERATURE REVIEW 
 
2.1 LITERATURE REVIEW 
 
According to the American Thoracic Society (2000), in order to treat Acute 
Respiratory Distress Syndrome (ARDS), appropriate antimicrobial treatment is 
needed to eliminate underlying causative pathogens. Most microbiological results 
only become available two to three days after cultures have been collected. 
Therefore, it is common clinical practice to initiate empirical antimicrobial treatment 
as soon as a diagnosis of ARDS is established (Leekha et al., 2010). No literature 
was found indicating a specific empirical antimicrobial treatment strategy for AIDS 
patients with ARDS. 
 
A common approach for empirical antimicrobial treatment of critically ill patients is 
the broad spectrum treatment; aimed at multiple (both typical and atypical) 
pathogens (Leekha et al., 2010). The main reason for so many clinicians opting for 
this approach is the fear of undertreating the critically ill patient, as delaying 
appropriate antimicrobial treatment is associated with a high mortality rate (Kollef, 
2008 and Kumar et al., 2006). In a study by Kumar et al (2006), the authors found 
a 79.9 percent survival rate when appropriate antimicrobial therapy was initiated 
within the first hour of sepsis presentation. Survival decreased by an average of 7.6 
percent for each hour of delay in the initiation of appropriate antimicrobial therapy. 
However, the broad spectrum approach can result in patients’ excessive exposure 
to (often inappropriate) antimicrobials; resulting in more adverse events and 
increased healthcare costs (Glowacki et al., 2003) as well as increased antimicrobial 
resistance (Leone and Martin, 2008). 
 
In an attempt to minimize the unwanted effects of a broad spectrum approach, Kollef 
(2008) advocates a de-escalation strategy where the broad spectrum antimicrobial 
treatment is narrowed down according to the pathogen(s) identified by 
microbiological tests.  However, clinicians are often hesitant to follow this strategy 
for a variety of reasons. These include unwillingness to change antimicrobial 
treatment that appears to be effective, perceived lack of trust in the sensitivity and 
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specificity of the microbiological tests, not understanding the de-escalating strategy 
and insufficient high quality evidence (Khasawneh et al., 2014).  
 
Another approach for empirical antimicrobial treatment of critically ill patients is 
pathogen-directed treatment. The advantage of a pathogen-directed approach is 
that it reduces risk of antimicrobial resistance and adverse events (van der Eeden 
et al., 2005) and thus also healthcare costs.  However, limiting the antimicrobial 
coverage to a pathogen-directed spectrum might undertreat patients with concurrent 
atypical infections (File, 2015).  
 
A prospective cohort study by Kollef et al (1999) described the relationship between 
inadequate antibacterial treatment and mortality for patients in the ICU with either 
community acquired or hospital acquired infections. The study was performed at 
Barnes-Jewish Hospital, a teaching hospital in St.Louis, Missouri. All infected 
patients admitted to this hospital’s ICU were elegible for the study. Antimicrobial 
treatment was considered inappropriate if the pathogen in the blood culture was not 
treated effectively (according to antibiotic susceptibility) at the time of identification. 
The main outcome parameter for this study was hospital mortality. The results of 
this study showed a significantly higher hospital mortality rate for the patients that 
received inadequate antibacterial treatment than for the patients that received 
adequate antibacterial treatment.  
 
The same conclusion was made by Valle’s et al (2003), who performed a similar 
study than Kollef et al (1999). The authors of this study examined the impact of 
inappropriate antimicrobial treatment on the outcome of critically ill patients in 30 
hospital ICUs in Spain. Adults admitted to these ICUs, with a minimum of one true 
positive blood culture, were eligible for this study. The outcome parameter for this 
study was survival. The authors found that inappropriate initial antimicrobial 
treatment was the most important determinant of survival for critically ill bacteremic 
patients in the ICU and the more severe the illness (presence of septic shock), the 
bigger the influence on survival rate (thus, reducing the survival rate). 
 
Both these studies on inappropriate antimicrobial cover support the empirical broad 
spectrum antimicrobial strategy that aims to avoid the high mortality rate associated 
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with initial inadequate cover. They do recommend de-escalation after culture results 
if appropriate. Both studies included immunocompromised patients as well as 
patients diagnosed with ARDS. 
 
However, studies that compared empirical broad spectrum and pathogen-directed 
antimicrobial treatment for hospitalised patients with community acquired 
pneumonia indicated no benefit in terms of clinical efficacy of initial broad spectrum 
antimicrobial treatment over pathogen directed antimicrobial treatment. One of 
these studies was a prospective randomised study by van der Eeden et al (2005). 
The study was performed at Alkmaar Medical Centre in The Netherlands. The 
authors decided on length of hospital stay as the main outcome parameter. 
Therapeutic failure on antimicrobial treatment, 30 day mortality and adverse events 
were the secondary outcome parameters. Statistical tests performed indicated no 
significant difference for the main and secondary outcome parameters between the 
two groups. The study did not limit its population to ICU patients only, but considered 
all patients admitted to the hospital with community acquired pneumonia. The study 
excluded patients with immunosuppression (HIV-infection) and did not disclose 
whether or not any of the study participants were diagnosed with ARDS.  
 
Another study was a retrospective cohort study by Williams et al (2013). The authors 
used data obtained from the Paediatric Health Information System database. This 
database contains clinical data of 43 tertiary care children’s hospitals in the United 
States. The main outcome parameter for this study was length of hospital stay and 
secondary outcome parameters were admission to the ICU after the first two days 
in hospital, a 14 day readmission rate and total cost for hospital admission. Again, 
statistical tests indicated no significant difference between the outcomes for the two 
groups. The study population was however children between the ages of 2 and 18 
years and not adults. They did not mention whether or not they included or excluded 
immunocompromised patients. They included patients admitted to both the general 
hospital wards and the ICU. However, they excluded patients that were admitted to 
the ICU or that were mechanically ventilated before two days of stay in hospital in 




According to the results of these two studies, pathogen-directed treatment seems 
to be the treatment of choice. This approach contributes less to the emergence of 
antimicrobial resistance and the increase in healthcare costs, without compromising 
the outcome of the patient. However, these studies did not focus on 
immunocompromised patients with ARDS and included patients in both the general 
ward and the ICU. Further studies that focus in specific on immunocompromised 
patients with ARDS in the ICU setting are needed in order to draw a valid conclusion. 





























CHAPTER 3. METHOD 
 
3.1 STUDY SETTING 
 
This study was conducted at a general private hospital in Richards Bay, Kwazulu-
Natal North Coast. The hospital has 263 beds and serves an urban as well as a 
peri-urban population. Richards Bay’s population consists of 57387 people; 48.01 
percent black African, 30.1 percent White, 18.22 percent Indian, 3.25 percent 
Coloured and 0.42 percent other (Frith, 2011). Figure 3.1 below is an image of a 




Figure 3.1 Richards Bay’s location in Kwazulu-Natal (SA Places, 2015). 
 
The hospital is situated in the centre of Richards Bay and offers the following 
specialities: Anaesthesiology, bio kinetics, dentistry, diagnostic radiology, 
ophthalmology, psychiatry, urology, audiology, cardiology, dermatology, neurology, 
gynaecology, physiotherapy and nephrology. The hospital also have the following 
surgeons: general surgeons, a neurosurgeon, orthopaedic surgeons, an ear, nose 
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and throat surgeon and a maxillo-facial and oral surgeon. Other specialists include 
physicians, intensivists, paediatricians and a neonatologist. Additional services 
include: general practitioners, 24-hour accident and emergency unit, wound care 
clinic, diabetic clinic, laboratories, retail pharmacy and stork’s nest. It is the only 
private hospital in Richards Bay and has three intensive care units (one medical, 
one surgical and one neonatal intensive care unit), a high care ward, two surgical 
wards, two medical wards, a paediatric ward, orthopaedic ward, cardiac ward, 
maternity ward and a day ward. The hospital has six theatres as well as a gastro-
intestinal unit.    
 
The hospital has an Antimicrobial Stewardship team as well as a Drug and 
Therapeutics Committee. The Antimicrobial Stewardship team consists of a 
pharmacist, an infectious diseases physician, an infection control nurse and a 
microbiologist. The Drug and Therapeutics Committee consists of the Antimicrobial 
Stewardship team, a representative clinician from each major speciality, the 
pharmacy manager, unit/ward managers of the hospital, the hospital manager and 
a laboratory technician. It is the function of this committee to develop in-house 
antimicrobial use guidelines, monitor the implementation of these guidelines, assess 
feedback and outcomes, and conduct reviews and potential revisions of these 
guidelines every year. 
 
3.2 STUDY POPULATION 
 
The population for this study was all HIV/AIDS infected patients admitted to the 
medical ICU of a private hospital in Richards Bay, KwaZulu-Natal with an ARDS 
diagnosis at time of admission or soon thereafter, between January 2013 and 
December 2013. 
 
3.3 STUDY SAMPLE 
 
Total population sampling, a type of purposive sampling technique, was performed 
for this study. This is a nonprobability sampling method that may be utilized when a 
target study population is small in size (Laerd Statistics, 2012). For this work, the 
hospital records of all HIV-infected medical ICU patients with an admitting (or soon 
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after admission) diagnosis of ARDS, between January 2013 and December 2013, 
that met study inclusion and exclusion criteria, were included in the study sample.  
 
3.4 INCLUSION AND EXCLUSION CRITERIA 
 
Hospital records of potentially eligible patients were reviewed according to a set of 
inclusion and exclusion criteria. The inclusion criteria for this study were that the 
patient: 1) had a confirmed diagnosis of AIDS, with a CD-4 count of less than 200 
cells per cubic millilitre blood; 2) had an admitting diagnosis/diagnosis soon after 
admission of ARDS; 3) was mechanically ventilated as a result of this diagnosis;  4) 
received either broad spectrum or pathogen-directed antimicrobial treatment;   5) 
was between the age of 18-65 years (to exclude age-related effects on prognosis); 
and 6) was admitted directly from Casualty into the medical ICU. This final criterion 
was instituted to exclude patients who had previously failed first line antimicrobial 
treatment and to exclude the effect of delayed ICU care on prognosis. All criteria 
had to be met in order for a patient (record) to be included in the study.  
  
Exclusion criteria for the study were that the patient: 1) did not meet the defined 
criteria above; 2) was pregnant at admission; 3) had an existing malignancy; 4) had 
a known antimicrobial drug allergy, or 5) had any of the following co-morbidities: 
COPD (chronic obstructive pulmonary disease), any other organ failure (apart from 
the lungs) or a pulmonary embolism. These criteria can influence the decision of 
antimicrobial choice other than expert opinion and/or can contribute to a worse 
prognosis for the patient other than the effect of the admission diagnosis, hence 
exclusion criteria. 
 
3.5 PARTICIPANT RECORD SCREENING, SELECTION, and TREATMENT 
GROUP ALLOCATION  
 
According to the medical ICU’s admission records, for the period January to 
December 2013, there were one hundred and seven patients with a diagnosis of 
ARDS. Sixty three of these patients were between the ages of 18 and 65 years and 
were admitted directly from Casualty into the ICU. Thirty patients met the remaining 
inclusion and exclusion criteria of the study. Based on the antimicrobials the patients 
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were initiated on, they were allocated to one of the two treatment groups. Twelve 
patients received treatment A (broad-spectrum) and eighteen patients treatment B 
(pathogen-directed). Specific antimicrobials included in each group are described in 




Figure 3.2 Participant record screening, selection and allocation to treatment 
groups. 
 
3.6 TREATMENT GROUPS 
 
At the hospital where this work was undertaken, the decision to treat with either 
broad spectrum or pathogen-directed treatment is based on clinician opinion 
regarding appropriate empirical antimicrobial treatment strategies for critically ill 
patients in the ICU. The broad spectrum approach is informally called “IV 
domestos*” by the facility’s clinicians. This approach consists of antimicrobials that 
cover multiple possible ARDS causative pathogens (both typical and atypical). This 
includes cover for gram positive bacteria, gram negative bacteria, Pneumocystis 
jirovecii, other fungal infections and, sometimes, viral infections. This broad 
spectrum approach consists of a minimum of four antimicrobials prescribed 
concurrently in order to cover this kind of microbial spectrum (Dr D Kelbe 2013, pers. 
comm, 13 June).  
 
*Domestos is a South African household cleaning product. It is marketed as a cleaning product that kills “all known germs” in the house. In the 
study facility, broad spectrum intravenous antimicrobial treatment is informally referred to by clinicians as “IV Domestos” in recognition of the 
fact that the treatment is aimed at the potential eradication of as many microbes as possible.  
107 Patients with ARDS 
diagnosis
63 Patients who met 
screening criteria 
30 Patients who met 
inclusion and exclusion 
criteria
12 Patient received 




The most common causative pathogens of ARDS are Pneumocystis jirovecii and 
Streptococcus pneumonia (Benito et al., 2012). The pathogen-directed approach at 
the study hospital is aimed at only these two pathogens. Pneumocystis jirovecii is 
treated with Suxamethonium-Trimethoprim and Streptococcus pneumonia with a 
combination of a beta-lactam antibiotic + macrolide/fluoroquinolone. The latter 
combination is based on the guideline for the treatment of community acquired 
pneumonia in the ICU of the American Thoracic Society (2007). At the hospital, the 
pathogen-directed approach consists of a maximum of three antimicrobials 
prescribed concurrently in accordance to this guideline (Dr D Kelbe 2013, pers. 
comm, 13 June). Table 3.1 and table 3.2 below summarize the antimicrobial 
combinations used for the two treatment groups, based on conventional clinician 
practice at the study hospital. 
 
Table 3.1 Treatment A. 
 
Treatment A (broad spectrum) 
 
Beta-lactam¹ antibiotic + Macrolide/Fluoroquinolone² + Antifungal³ + 
Aminoglycoside + Suxamethonium-Trimethoprim + Anti-viral 
 
¹Ceftriaxone (3rd generation cephalosporin) or Amoxycillin+clavulanic acid/Piperacillin+ tazobactam (beta-lactamase resistant penicillins). 
²Levofloxacin or Moxifloxacin 
Patients allocated to this treatment group concurrently received a minimum of any 
4 of the above antimicrobials. 
 
Table 3.2 Treatment B. 
 
Treatment B (pathogen-directed) 
 
Beta-lactam¹ antibiotic + Macrolide/fluoroquinolone² + Suxamethonium-
Trimethoprim 
 
¹Ceftriaxone (3rd generation cephalosporin) or Amoxycillin+clavulanic acid/Piperacillin+ tazobactam (beta-lactamase resistant penicillins). 
²Levofloxacin or Moxifloxacin 
Patients allocated to this treatment group concurrently received a maximum of 
any 3 of the above antimicrobials. 
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3.7 DATA COLLECTION TOOLS 
 
Data collection sheets were used for the selecting and screening of patient records 
and to display the data extracted from these records. A total of six data collection 




The first data collection sheet was designed in order to screen the Medical ICU’s 
admission records. This sheet allowed screening for patients with an admission 
diagnosis of ARDS (or soon thereafter), that were admitted directly from Casualty 
into the ICU and that were between 18 and 65 years of age. 
 
Tool #2 
The second data collection sheet was designed for a second level of screening. 
Patient records (that met the criteria on the first data collection sheet) were screened 
for remaining inclusion and exclusion criteria. The criteria had to be answered with 
either a “yes” or a “no”. The answers had to be all “yes” for the inclusion criteria and 
all “no” for the exclusion criteria in order to be included in this study. 
 
Tool #3 
The third data collection sheet was designed in order to specify the antimicrobial 
treatment the patient received for easy classification of patients to either treatment 
group A or treatment group B. The broad spectrum treatment approach was named 
“treatment A” and the pathogen-directed approach “treatment B”.  
 
Tool #4 
The fourth data collection sheet was designed for comparing the patient 
characteristics of the two treatment groups. The patient characteristics that needed 
to be collected included: patient age, sex, any other co-morbidities not listed under 







The fifth data collection sheet was designed in order to compare culture results of 
the two treatment groups. Information on the data collection sheet included: 
organism(s) cultured, culture source, time from initiation of antimicrobial treatment 




The sixth data collection sheet was designed to collect the outcome results of the 
patients of the two treatment groups. The main outcome parameter for this study 
was survival rate to ICU discharge. The secondary outcome parameters were total 
length of ICU stay and total duration of antimicrobial treatment. The following 
questions on the data sheet had to be answered per included patient regarding the 
outcome parameters: 
 Did the patient survive until discharged from the ICU: Yes/No  
 What was the total length of ICU stay: Measured in number of days. 
 What was the total duration of antimicrobial treatment in the ICU: Measured 
in number of days. 
 
3.8 DATA COLLECTION PROCESS 
 
Objectives 1 to 3: 
 




The first phase was the initial screening of medical ICU admission records for 
patients with an admitting ARDS diagnosis or for whom this diagnosis was made 
soon thereafter. Eligible patient records included those for patients between the 
ages of 18 and 65 years who were admitted directly from Casualty into the ICU. The 
records of the patients that met this initial set of criteria were then requested from 





The second phase was a second level of screening. The requested patient records 
were further screened according to the remainder inclusion and exclusion criteria of 
this study.  
 
Phase #3 
Phase three was allocation of the included patient records to one of the two 
treatment groups. The allocation was based on the antimicrobial treatment the 
patient was initiated on during the first 24 hours following admission. Patients that 
received broad spectrum antimicrobial treatment were allocated to treatment group 
A and patients that received pathogen-directed treatment were allocated to 
treatment group B.  
 
Phase #4 
Phase 4 was the collection of information from the included patient records per 
treatment group.  Information collected included information regarding patient 





The fourth objective of this study was to formulate a set of in-house guidelines 
regarding antimicrobial treatment of ARDS in AIDS patients admitted to the medical 
ICU. The guidelines derived from study results were drafted taking into account 
hospital requirements for adopting new treatment guidelines.  
 
The prerequisites for recommending an antimicrobial guideline to the hospital’s Drug 
and Therapeutics Committee (and in accordance with the WHO’s prerequisites for 
treatment guidelines, 2011) are: 1) the choice of the antimicrobials recommended 
should be based on the hospital’s microbiological test results, 2) it should be 
syndrome based, 3) the clinical setting must be specified as well as the rationale for 
recommending the guideline, 4) it should provide the strength (evidence-based) of 
the recommendation and it should involve the hospital’s clinicians in order to bring 
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ownership to the guidelines. The guideline should lead to appropriate use of 
antimicrobials and limit the emergence of antimicrobial resistance (WHO, 2011).  
 
3.9 DATA MANAGEMENT 
 
The raw data were stored electronically on a password protected computer on the 
hospital’s premises and will be kept for a duration of 5 years from the time of study 
write up. Only the author of this study will have access. After 5 years, the raw data 
will be deleted from the researcher’s computer hard drive and any hard copies will 
be destroyed. 
 
3.10 ETHICAL CONSIDERATIONS AND CONFIDENTIALITY 
 
Permission to conduct the research was obtained from the study hospital itself as 
well as from the hospital’s Research Operational Committee. Ethics approval was 
obtained from the Biomedical Research Ethics Committee (BREC) of the University 
of KwaZulu-Natal. Only the hospital's patient record numbers were used on data 
sheets, and no patient can be identified by name. Electronic records of data 
collected during the study were stored securely and strict access control measures 

















CHAPTER 4. DATA ANALYSIS AND RESULTS 
 
4.1 DATA ANALYSIS 
 
The software package STATISTICA (StatSoft Inc. 2013) was used for the analysis 
of the data collected for this study. 
 
Participants’ socio-demographic profile: 
 
The first step in data analysis was to compare the socio-demographic profiles of the 
two treatment groups.  Median age and gender ratios were determined for each 
treatment group. The median age was determined instead of the proposed mean 
due to the small sample size (thirty patients) and small sample size in treatment 
groups (twelve patients in treatment group A and eighteen patients in treatment 
group B). Gender is nominal data and these values were counted and presented as 
a ratio for each treatment group. Co-morbidities are also nominal data and the 
percentage for each identified co-morbidity as well as for tuberculosis and smoking 
status were calculated. 
 
Patient outcome by objective: 
 
Data analysis for the first three objectives of the study was done in two ways: 1) 
culture “blind” and 2) cultures “revealed”. For the culture “blind” analysis, the 
outcome parameters were compared between the two treatment groups based on 
an approach where antimicrobial therapy is initiated empirically (thus, before culture 
results are known) and that the physicians do not de-escalate broad spectrum 
antimicrobial treatment after culture results for a variety of reasons (Khasawneh et 
al., 2014). For the cultures “revealed” analysis, outcomes were compared between 
the two treatment groups for patients with the same culture result. Further, choice 
to initiate either pathogen-directed or broad spectrum treatment is very often based 
on clinician opinion. This was also borne out in informal discussions with clinicians 







Objective 1 - Comparing survival rate to ICU discharge between broad spectrum 
and pathogen-directed antimicrobial treatment: 
 
The first objective for this study was to compare the survival rate to ICU discharge 
(main outcome parameter) between broad spectrum and pathogen-directed 
antimicrobial treatment of ARDS among patients with AIDS in the ICU setting. 
Survival rate is defined as a percentage of study participants alive for a certain 
period of time after diagnosis or initiation of treatment (Gordis, 2000). 
 
Survival analysis is a method for analysing data where the outcome variable has 
two components: time to event and event status (censored or uncensored). The 
event of interest for this study was ICU discharge. For this analysis, the earlier the 
exit/time to event of interest (discharge from ICU) the better the patient outcome. 
When study participants do not experience the event of interest (e.g. if the patient 
died), the observations are called “censored”, as the information on the survival time 
is incomplete. Although censoring indicates a type of missing data, certain survival 
methods (e.g. Kaplan-Meier) can accurately incorporate censored and uncensored 
observations.  
 
The Kaplan-Meier method is a nonparametric estimator of the survival function, and 
is used to estimate and graph survival percentages as a function of time (Despa, 
2005). In this graphical depiction, the y-axis represents cumulative survival 
percentages and the x-axis time after initiation of treatment (Goel, Khanna and 
Krisha, 2010).  In order to compare two Kaplan-Meier curves statistically for two 
treatment groups, the null hypothesis of “no difference” can be tested.  This can be 
done by means of various available tests, with the log-rank test (also called the 
Mantel-Cox test) being the most popular (Despa, 2005). This nonparametric test, 
with significance level of alpha (α) = 0.05, was used in this study. If the calculated 
p-value is ≤ α, then the null hypothesis is rejected. If p > α, then the null hypothesis 
is not rejected.  The log-rank test was used, instead of the commonly used student-




Objective 2 - Comparing length of ICU stay between broad spectrum and pathogen-
directed antimicrobial treatment: 
 
The second objective for this study was to compare the length of stay in the ICU 
(secondary outcome parameter) between pathogen-directed and broad spectrum 
antimicrobial treatment of ARDS among AIDS patients in the ICU. 
 
In order to determine the distribution of the data, the values for length of stay in ICU 
in days (x-axis) for the surviving patients were graphed (graph 4.1) as a histogram 
(number of observations (y-axis)). This was important in order to determine whether 
parametric or non-parametric tests were appropriate to use. Data distribution is 
considered normal if the histogram creates a curve with a bell-shape (Roberts, 
2012). This illustrates the state in which most values cluster in the centre of the data 
range (this creates a central peak and is also the mean of the data); with the 
remaining values tapering off symmetrically towards the data extremes (Rouse, 
2013). In graph 4.1 below, it is clear that the data of this study were non-normally 
distributed, as the histograms did not create a bell-shaped curve. 
 
Categorical Histogram: ICU days
Frequencies for no. of days in ICU, by treatment groups
























-5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70
 
 
Graph 4.1 Distribution of the data values for length of stay in ICU (in days) for 




For this objective the difference in median number of days in the ICU was analysed 
between the surviving patients of the two treatment groups (seven patients in 
treatment group A and eleven patients in treatment group B). The median value was 
used instead of the mean because of the non-normal distribution of the data. The 
most suitable test for comparing the two medians for the two independent samples 
was the Kruskal-Wallis H test with significance level alpha (α) = 0.05. This test is a 
rank-based, nonparametric test that does not require the assumption of normality 
and can be used to test if there are statistically significant differences between two 
or more groups of an independent variable on a continuous or ordinal dependent 
variable (Laerd Statistics, 2012). If the calculated H statistic of the Kruskal-Wallis 
test is less than the critical value (read off from the Kruskal-Wallis H distribution 
table), then the null hypothesis cannot be rejected. If the calculated H statistic is 
greater than the critical value, then the null hypothesis can be rejected at the 
specified alpha level (Statistics Solutions, 2015). The treatment that resulted in a 
shorter length of stay in the ICU was the treatment with the better patient outcome. 
 
Objective 3 - Comparing duration of antimicrobial treatment between broad 
spectrum and pathogen-directed antimicrobial treatment: 
 
The third objective for this study was to compare the duration of antimicrobial 
treatment (secondary outcome parameter) between broad spectrum and pathogen-
directed antimicrobial treatment of ARDS among AIDS patients in the ICU.  
 
In order to determine the distribution of the data, the values for duration of 
antimicrobial treatment in ICU in days (x-axis) for the surviving patients were 
graphed (graph 4.2) as a histogram (number of observations (y-axis)). In graph 4.2 
below, it is clear that the data of this study were non-normally distributed, as the 
histograms did not create a bell-shaped curve. 
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Graph 4.2 Distribution of the data values for duration of antimicrobial treatment in 
ICU (in days) for treatment groups A and B.  
 
For this objective the difference in median number of treatment days in the ICU was 
analysed between the surviving patients of the two treatment groups (seven patients 
in treatment group A and eleven patients in treatment group B). The median value 
was used instead of the mean because of the non-normal distribution of the data. 
The Kruskal-Wallis H test with significance level set at alpha (α) = 0.05 was again 
the most suitable test to compare the two medians for the two independent samples. 
The treatment that resulted in the shortest duration of antimicrobial treatment was 
the treatment with the better patient outcome. 
 
Box-and Whisker plots, a type of graph that shows the shape of the data distribution 
(Easton and McColl, 1997), were used to describe the median length of ICU stay 
and duration of antimicrobial treatment for treatment groups A (broad spectrum) and 










The first step in analysis under cultures “revealed” was comparison of culture 
results. For culture results (nominal data) for the two treatment groups, a percentage 
was calculated for patients for whom cultures were done, the organisms cultured, 
the culture source and the percentage of de-escalation that took place after culture 
results. Time is ratio data (which is interval data with an absolute zero point (Easton 
and McColl, 1997)) and therefore the minimum and maximum times from initiation 
of antimicrobial treatment until culture results were received were determined. 
 
Objective 1 - Comparing survival rate to ICU discharge between broad spectrum 
and pathogen-directed antimicrobial treatment: 
 
The first objective for this study was to compare the survival rate to ICU discharge 
(main outcome parameter) between broad spectrum and pathogen-directed 
antimicrobial treatment of ARDS among ICU patients with AIDS. Due to the small 
sample size (five surviving patients – one in treatment group A and four in treatment 
group B) for the cultures “revealed” analysis, it was not viable to perform any formal 
statistical tests for this data. Because of this, the two treatment groups were 
compared by only looking at the percentage of surviving patients, with Pneumocystis 
jirovecii cultured, discharged at certain points in time (the number of days spent in 
the ICU per patient); with the focus on the number of days it took to achieve a 100 
percent discharged percentage. The shorter the duration to achieve a 100 percent 
discharged percentage, the better the patient outcome. 
 
Objective 2 - Comparing length of ICU stay between broad spectrum and pathogen-
directed antimicrobial treatment: 
 
The second objective for this study was to compare the length of stay in the ICU 
(secondary outcome parameter) between pathogen-directed and broad spectrum 
antimicrobial treatment of ARDS among AIDS patients in the ICU. Again, no formal 
statistical tests were performed due to small sample size (five surviving patients – 
one in treatment group A and four in treatment group B). The median length of ICU 
stay (in number of days) were calculated for the patients in treatment group A and 
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B with Pneumocystis jirovecii cultured. The shorter the length of stay in the ICU, the 
better the patient outcome. 
 
Objective 3 - Comparing duration of antimicrobial treatment between broad 
spectrum and pathogen-directed antimicrobial treatment: 
 
The third objective for this study was to compare the duration of antimicrobial 
treatment (secondary outcome parameter) between broad spectrum and pathogen-
directed antimicrobial treatment of ARDS among AIDS patients in the ICU. No 
formal statistical tests were performed due to small sample size (five surviving 
patients – one in treatment group A and four in treatment group B). The median 
duration of antimicrobial treatment (in number of days) was calculated for the 
patients in treatment group A and B with Pneumocystis jirovecii cultured. The shorter 
the duration of antimicrobial treatment, the better the patient outcome. 
 
Objective 4 - Formulation of an In-House Set of Guidelines: 
 
The fourth objective of this study was to formulate an in-house set of guidelines. The 
compilation of a set of draft guidelines took place based on the analysis of all data 
collected during the study period. 
 
The steps followed to formulate the draft in-house antimicrobial guideline were 
based on the prerequisites set by the Drug and Therapeutics committee of this 
hospital. These steps included: 1) Writing the guideline in specific for the 
antimicrobial treatment of HIV infected patients with ARDS in the ICU of the study 
site hospital; 2) specifying and describing the clinical setting in the guideline; 3) 
indicating that the guideline was based on this hospital’s microbiological test and 
study results; 4) describing the rationale for recommending this guideline; 5) 
specifying the recommended antimicrobial treatment (based on this study’s results) 
as well as the strength (evidence-based) of the recommendation. The next step 
would then be to 6) arrange the presentation and recommendation of the draft 
guideline onto the agenda of the next Drug and Therapeutics committee meeting 






Participants’ socio-demographic profile: 
 
The median age for treatment group A (broad spectrum) and group B (pathogen-
directed) was 38 and 40 years respectively. With respect to gender, half (50%) of 
treatment group A were male and half (50%) female patients. In treatment group B 
38.9 percent were male and 61.1 percent were female. There were no smokers in 
either of the two treatment groups. This information is presented below in table 4.1. 
 
Table 4.1 Participants’ socio-demographic profile. 
 
 
With respect to co-morbidities, nearly all (91.7%) patients in treatment group A had 
some form of tuberculosis.  Among those with tuberculosis, two thirds (66.7%) had 
pulmonary tuberculosis, 16.7 percent had multi-drug resistant pulmonary 
tuberculosis and 8.3 percent had abdominal tuberculosis. In treatment group B, 72.2 
percent of the patients had pulmonary tuberculosis. See the comparative 










 Total sample size n=30 
 
Group A (broad spectrum) 
n=12 




Minimum Median Maximum 
 
Minimum Median Maximum 
Age in years 
 
23 38 47 
 
25 40 64 
Gender 
Male : Female 50% : 50% 39% : 61% 
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In treatment group A, 16.6 percent patients had other co-morbidities. These 
included: diabetes (8.3 percent of the patients) and anaemia (8.3%). In treatment 
group B there were 33.3 percent patients with other co-morbidities; including 
hypertension (5.6 percent of the patients), pericardial effusion (5.6%), deep vein 
thrombosis (5.6%), psychosis (5.6%), hypertension and diabetes (5.6%) and 
hypertension, diabetes and asthma (5.6%).  
 




Objective 1 – Comparing survival rate to ICU discharge of pathogen-directed with 
broad spectrum antimicrobial treatment: 
 
The first objective of this study was to compare survival rate to ICU discharge (main 
outcome parameter) between pathogen-directed and broad spectrum antimicrobial 
treatment for ARDS among ICU patients with AIDS. To reiterate, survival rate is 
defined as a percentage of study participants alive for a certain period of time (until 
event of interest; in this case survival to ICU discharge) after diagnosis or initiation 
of treatment (Gordis, 2000). In this study, twelve of the thirty included patients died 
Tuberculosis (TB) % 
Total sample size n=30 
Group A (broad spectrum) 
n=12 





















Total % with 
TB 




without TB  





prior to discharge/while in the ICU. Thus data analysis for this section was right 
censored. Although the Kaplan-Meier analysis can take right-censored data into 
account, these censored observations skewed the survival curve(s) in the sense 
that it appeared to shorten the time to discharge. For example, when the Kaplan-
Meier curves for the two treatment groups were compared (with censored data 
included) using Cox’s F test, a p-value of 0.24 was obtained (at significance level of 
alpha = 0.05). This suggests a non-significant difference. Moreover, examination of 
the survival curve (graph 4.3) shows that most patients in treatment group B 
experienced the event of interest (ICU discharge) within 30 days (horizontal/x-axis). 
By comparison, for most patients in treatment group A, ICU discharge only occurred 
by 50 to 60 days. See graph 4.3 below. 
 
Cumulative Proportion of Surviving Patients 
(Kaplan-Meier)



























































Graph 4.3 Kaplan-Meier survival curves demonstrating cumulative percentage of 
patients surviving after x number of days in the ICU for both censored and 
uncensored patients of treatment groups A and B. 
 
When comparing the Kaplan-Meier curves (graph 4.4) of the two treatment groups 
for only the censored patients (those who died in ICU – five patients in treatment 
group A and seven patients in treatment group B), the Log-rank test, yielded p=0.82 
(alpha = 0.05). This indicates that there is no significant difference between the 
survival curves for the two treatment groups. Thus, removing these 12 censored 
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observations should not have an impact on the remainder of the data. See graph 
4.4 below. 
 
Cumulative Proportion of Surviving Patients : Censored (Kaplan-Meier)
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Graph 4.4 Kaplan-Meier survival curves demonstrating cumulative percentage of 
patients surviving after x number of days in the ICU for censored patients of 
treatment groups A and B. 
 
The focus now lies on the uncensored patients (seven surviving patients in 
treatment group A and eleven surviving patients in treatment group B). The 
statistical Log-rank test, with significance level alpha = 0.05, indicated a significant 
difference between the outcomes for treatment A and B (Log-Rank p = 0.02), thus 
rejecting the null hypothesis of equality. The period of time until the event of interest 
occurred for 50 percent surviving patients (also known as median survival rate) was 
43 days for treatment group A and 17 days for treatment group B (as read off from 
graph 4.5). This means that the period of time for treatment group B (pathogen-
directed) to have 50 percent surviving patients discharged, was shorter than the 
period of time for treatment group A (broad spectrum) to have 50 percent surviving 
























































Graph 4.5 Kaplan-Meier survival curves demonstrating cumulative percentage of 
patients surviving after x number of days in the ICU for uncensored patients of 
treatment groups A and B. 
 
Objective 2 - Comparing length of ICU stay between broad spectrum and pathogen-
directed antimicrobial treatment: 
 
The second objective focused on a comparison of the length of ICU stay between 
pathogen-directed and broad spectrum antimicrobial treatment. Total length of ICU 
stay was one of the secondary outcome parameters for this study. 
 
The Kruskal-Wallis test, with significance level of alpha = 0.05 and critical value 
3.84, confirmed a significant difference (calculated test statistic H = 3.97) between 
the length of ICU stay for the survivors in treatment groups A and B (seven in 
treatment group A and eleven in treatment group B). The median length of stay in 
the ICU was 43 days for treatment group A (broad spectrum) and 17 days for 
treatment group B (pathogen-directed). Thus, treatment group B had a shorter 
length of ICU stay than treatment group A. Median, minimum and maximum values, 
and inter-quartile (25th (Q1) to 75th (Q3) percentile) ranges are shown in the Box-













































Graph 4.6 Box-and –Whisker plots demonstrating median, minimum and maximum 
values, and inter-quartile (25th (Q1) to 75th (Q3) percentile ranges for length of ICU 
stay (in days) for treatment groups A and B. 
 
Objective 3 - Comparing duration of antimicrobial treatment between broad 
spectrum and pathogen-directed antimicrobial treatment: 
 
Comparing the duration of antimicrobial treatment between pathogen-directed and 
broad spectrum treatment when treating ARDS in patients with AIDS in the ICU was 
the third objective for this study. Total duration of antimicrobial treatment was also 
one of the secondary outcome parameters for this study. The Kruskal-Wallis test, 
with significance level of alpha = 0.05 and critical value 3.84, confirmed a significant 
difference (test statistic H = 3.97) between the duration of antimicrobial treatment 
for the survivors in treatment group A and B (seven in treatment group A and eleven 
in treatment group B). The median duration of antimicrobial treatment was 43 days 
for treatment group A (broad spectrum) and 17 days for treatment group B 
(pathogen-directed). Thus, treatment group B had a shorter duration of antimicrobial 
treatment than treatment group A. Median, minimum and maximum values, and 
inter-quartile (25th (Q1) to 75th (Q3) percentile) ranges are shown in the Box-and -
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Graph 4.7 Box-and –Whisker plots demonstrating median, minimum and maximum 
values, and inter-quartile (25th (Q1) to 75th (Q3) percentile ranges for duration of 




Participants’ culture results: 
 
Cultures were done for all patients in both treatment groups. The minimum amount 
of time it took from initiation of treatment until cultures were received for both 
treatment groups was 1 day and the maximum amount of time for treatment group 
A (broad spectrum) was 5 days and for treatment group B (pathogen-directed) 6 
days. For treatment group A, organism growth was detected for 41.7 percent of 
patients. Pneumocystis jirovecii was cultured for 8.3 percent of the patients with 
sputum the culture source. Pneumocystis jirovecii and Staphylococcus aureus were 
cultured for 16.7 percent of the patients and sputum was again the culture source, 
except for one patient where a nasal swab was the culture source for the cultured 
Staphylococcus aureus. Klebsiella pneumoniae and Pseudomonas aeruginosa 
were cultured for 8.3 percent of the patients and sputum was the culture source. 
Staphylococcus epidermidis and Klebsiella pneumoniae were cultured for 8.3 
percent of the patients and the culture source for Staphylococcus epidermidis was 
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blood and the axilla for Klebsiella pneumoniae. There was no organism growth for 
58.3 percent of the patients in treatment group A.  
 
For treatment group B, organism growth was detected for 44.4 percent of patients. 
Pneumocystis jirovecii was cultured for 33.3 percent of the patients with sputum the 
culture source, except for one patient where the bronchial washings was the culture 
source. Candida albicans was cultured for 5.6 percent of the patients with sputum 
the culture source. Staphylococcus epidermidis and Pneumocystis jirovecii were 
cultured for 5.6 percent of the patients with blood the culture source for 
Staphylococcus epidermidis and sputum for Pneumocystis jirovecii. There was 
however no organism growth for 55.6 percent of the patients in treatment group B. 

























Table 4.3 Comparative culture results for the two treatment groups. 
 
 
At the hospital where this study was undertaken, both pathogen-directed and broad 
spectrum antimicrobial treatments are initiated empirically (before culture results are 
known). Most clinicians at this hospital do not de-escalate broad-spectrum treatment 
after culture results, because they want to ensure cover for both multiple (typical 
and atypical) pathogens at all times as they fear undertreating their critically ill 
patient (Dr D Kelbe 2013,  pers. comm, 13 June). The clinicians that treat with the 
pathogen-directed treatment also do not change treatment after culture results, 
unless an organism that causes an infection is cultured that is not covered by the 
pathogen-directed antimicrobial spectrum. The organism cultured most for the 
pathogen-directed treatment group in this study was Pneumocystis jirovecii. 
Although Streptococcus pneumonia was not cultured for any patients in this group, 
 Participants’ culture results 
 Total sample size n=30 
 Group A (broad spectrum) 
n=12 
Group B (pathogen-directed) 
n=18 











Pneumocystis Jirovecii 8.3% Sputum 33.3% Bronchial 
washings : 
Sputum (1 : 5) 
Pseudomonas Aeruginosa 
and Klebsiella Pneumonia 
8.3% Sputum   
Staphylococcus Aureus and 
Pneumocystis Jirovecii 
16.7% Nasal swab : 
Sputum (1 : 3) 
  
Staphylococcus Epidermidis 
and Klebsiella Pneumonia 
8.3% Blood :       
Axilla (1 : 1) 
 
Staphylococcus Epidermidis 
and Pneumocystis Jirovecii 
  5.6% Blood 
and sputum 
Candida Albicans   5.6% Sputum 
Total % growth 41.7% 44.4% 
Total % no growth 58.3% 55.6% 
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the clinicians continued with antimicrobial treatment aimed at this organism. 
Explanations for this include a lack in trust in the sensitivity and specificity of the 
diagnostic tests as well as a reluctance to change antimicrobial treatment that 
appears to be effective (Dr D Kelbe 2013, pers. comm, 13 June). 
 
Another problem regarding culture result “trust” at this hospital is that antimicrobial 
treatment is often initiated before adequate cultures are taken (Sr L Maurel 2014, 
pers. comm, 30 October). Obtaining cultures after antimicrobial treatment has been 
initiated can cause inconclusive culture results, because organisms that would 
otherwise be detected may not necessarily grow after antimicrobial exposure (Rojo, 
2006). This could also be a possible explanation for the high percentage of “no 
growth” culture results that were seen with this study.  
 
Objective 1 – Comparing survival rate to ICU discharge of pathogen-directed with 
broad spectrum antimicrobial treatment: 
 
For reasons related to small sample size (n=5), comparison of survival rate to 
discharge was undertaken only through examination of percentage of patients 
discharged at certain points in time, with the focus on the number of days it took to 
achieve a 100% discharged percentage. For treatment group A (broad spectrum), 
all (100%) survivors with Pneumocystis jirovecii cultured were discharged by 7 days. 
For treatment group B (pathogen-directed), 25 percent of survivors with 
Pneumocystis jirovecii cultured were discharged by 7 days, 50 percent by 18 days, 
75 percent by 24 days and 100 percent by 32 days only. As noted above, no formal 
statistical tests were performed due to small sample size (five surviving patients – 
one in treatment group A and four in treatment group B). 
 
Objective 2 - Comparing length of ICU stay between broad spectrum and pathogen-
directed antimicrobial treatment: 
 
The median length of ICU stay for the patients with Pneumocystis jirovecii cultured 
in treatment group A, was 11 days. The median length of ICU stay for the surviving 
patients with Pneumocystis jirovecii cultured in Treatment group B, was 21 days. No 




Objective 3 - Comparing duration of antimicrobial treatment between broad 
spectrum and pathogen-directed antimicrobial treatment: 
 
The median duration of antimicrobial treatment for the patients with Pneumocystis 
jirovecii cultured in treatment group A, was 11 days. The median duration of 
antimicrobial treatment for the survivors with Pneumocystis jirovecii cultured in 
treatment group B, was 21 days. No formal statistical tests were performed due to 
small sample size. 
 
See table 4.4 below for a summary of results for both the culture “blind” and 

























Table 4.4 Summary of results; culture “blind” and cultures “revealed”. 
 Culture “blind” results 
Total sample: n=30 
Uncensored: n=18 
Censored: n=12 
Cultures “revealed” results 
Total sample: n=7 
Uncensored: n=5 
Censored: n=2 
Objective 1 – 
Comparing survival 
rate to ICU discharge 
of pathogen-directed 




Total survivors: n=18 
Group A: n=7 
Group B: n=11 
 
Results: Null hypothesis rejected (p 
< α; α = 0.05).  
Group A: 50% surviving patients 
discharged by 43 days (median 
survival rate). 
Group B: 50% surviving patients 
discharged by 17 days (median 
survival rate). 
 
Total survivors: n=5 
Group A: n=1 
Group B: n=4 
 
Results:  
Group A: 100% surviving 
patients discharged by 7 
days. 
Group B: 100% surviving 
patients discharged by 32 
days. 
Objective 2 - 
Comparing length of 
ICU stay between 





Total survivors: n=18 
Group A: n=7 
Group B: n=11 
 
Results: Null hypothesis rejected (H 
≥ 3.84 (critical value); α = 0.05). 
Group A: Median length of ICU stay 
was 43 days. 
Group B: Median length of ICU stay 
was 17 days. 
 
Total survivors: n=5 
Group A: n=1 
 Group B: n=4 
 
Results: 
Group A: Median length of 
ICU stay was 11 days. 
Group B: Median length of 
ICU stay was 21 days. 









Total survivors: n=18 
Group A: n=7 
Group B: n=11 
 
Results: Null hypothesis rejected (H 
≥ 3.84 (critical value); α = 0.05). 
Group A: Median duration of 
antimicrobial treatment was 43 days. 
Group B: Median duration of 
antimicrobial treatment was 17days. 
Total survivors: n=5 
Group A: n=1 
Group B: n=4 
 
Results: 
Group A: Median duration of 
antimicrobial treatment was 
11 days. 
Group B: Median duration of 




Objective 4 - Formulating a set of in-house guidelines: 
 
The fourth objective of this study was to formulate an in-house guideline regarding 
antimicrobial treatment of ARDS among AIDS patients admitted to the ICU based 
on study results.  
 
This draft in-house treatment guideline was written specifically for the antimicrobial 
treatment of HIV infected patients with ARDS in the ICU of the study site hospital. 
The clinical setting was described and it was indicated that the guideline was based 
on this hospital’s microbiological test results. The rationale for recommending this 
guideline was also explained. The recommended antimicrobial treatment was based 
on this study’s results.  
 
Retrospective comparative therapeutic studies, investigating the results of 
treatment, are considered level three evidence according to the Levels of Evidence 
chart by De Vries and Berlet (2010). This study was a retrospective comparative 
study and therefore it was graded as level three evidence. The study was started 
after treatment was completed and participants were identified for the study based 
on the treatment they received. 
 
Hospital management’s secretary will be contacted in order to schedule the 
presentation and recommendation of this draft in-house guideline onto the agenda 
of the next Drug and Therapeutics Committee meeting in 2016. See Annexure B for 

















The null hypothesis for this study was as follow: 
 
There is no difference in patient outcomes when comparing broad spectrum 
antimicrobial and pathogen-directed treatment of ARDS among AIDS patients 
in the intensive care unit (ICU) setting. 
 




For the first objective of this study, there was a significant difference in patient 
outcome between the two treatment groups. Treatment group B (pathogen-directed) 
showed a better median survival rate (main outcome parameter) than treatment 
group A (broad spectrum), since the time it took (in number of days) to have 50 
percent patients discharged was shorter than for treatment group A.  
 
The broad spectrum approach also did not show a better outcome than the 
pathogen-directed approach in studies by van der Eeden et al (2005) and Williams 
et al (2013). These authors compared pathogen-directed with broad spectrum 
antimicrobial treatment for patients with community acquired pneumonia and found 
no significant difference in 30 day mortality rate between the two treatment groups. 
 
Antimicrobial resistance is a pressing international concern (World Health 
Organization, 2013) with excessive and prolonged antimicrobial treatment the main 
contributing factors in hospitals (MacDougall and Polk, 2005). Pathogen-directed 
antimicrobial treatment is aimed at the most likely causative pathogen(s) associated 
with a patient’s presenting condition (Leekha et al., 2010) and reduces the risk of 
antimicrobial resistance and adverse events (van der Eeden et al., 2005) and also 
healthcare costs (Glowacki et al., 2003). 
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The concern with limiting the antimicrobial coverage to a pathogen-directed 
spectrum is the possibility of undertreating patients with concurrent atypical 
infections (File, 2015). Initial inadequate antimicrobial cover can result in a higher 
hospital mortality rate (Kollef et al., 1999 and Valle’s et al., 2003) and that is the 
reason why many clinicians at the study site hospital treat ARDS among patients 
with AIDS in the ICU with the broad spectrum antimicrobial approach (Dr D Kelbe 
2013, pers. comm, 13 June). 
 
However, the results for the first objective of this study indicated that excessive 
antimicrobial coverage (broad spectrum approach) did not give a better outcome in 
terms of survival when treating ARDS among AIDS patients in the ICU at this 
hospital. Thus, the pathogen-directed antimicrobial approach was the treatment that 
resulted in a higher survival rate and theoretically contributed the least to the 
emergence of antimicrobial resistance. 
 
For the second objective of this study, there was also a significant difference in 
patient outcome between the two treatment groups. The median length of ICU stay 
(secondary outcome parameter) for the surviving patients in treatment group B 
(pathogen-directed) was shorter than for those in treatment group A (broad 
spectrum). The shorter length of ICU stay indicated that the event of interest, 
discharged from the ICU, was reached sooner for the pathogen-directed treatment 
group. 
 
In a study by van der Eeden et al (2005), the authors compared pathogen-directed 
with broad spectrum antimicrobial treatment for patients with community acquired 
pneumonia and found no significant difference in length of stay between the two 
treatment groups. Again, the broad spectrum approach did not show a better 
outcome than the pathogen-directed approach.  
 
For the third objective of this study, there was also a significant difference in patient 
outcome between the two treatment groups. The median duration of antimicrobial 
treatment for the surviving patients in treatment group B (pathogen-directed) was 
shorter than for those in treatment group A (broad spectrum). The shorter duration 
of antimicrobial treatment indicated that the event of interest, discharge from the 
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ICU, was reached sooner for the pathogen-directed treatment group. A shorter 
duration of antimicrobial treatment also theoretically contributes less to the 
emergence of antimicrobial resistance (MacDougall and Polk, 2005). 
 
Treatment group B (pathogen-directed) showed a better outcome regarding both 
the main and secondary outcome parameters of this study. The sample size of this 
analysis was small. A larger study is necessary to confirm the results of this analysis.  
If a larger study confirms that the pathogen-directed approach is the approach that 
results in better patient outcomes and this approach is approved by the Drug and 
Therapeutics committee for an in-house antimicrobial treatment guideline for AIDS 
patients with ARDS in the ICU, it will ensure optimal patient outcome and 




Due to the small sample size for this analysis, it was not viable to perform any formal 
statistical tests for the data of objectives 1- 3.  
 
For objective one, there was a difference in patient outcome between the two 
treatment groups. Treatment group A (broad spectrum) showed a better outcome 
than treatment group B as 100 percent survivors, for whom Pneumocystis jirovecii 
was cultured, were discharged after a shorter duration of stay in the ICU. 
 
For objective two, there was a difference in patient outcome between the two 
treatment groups. The median length of ICU stay (secondary outcome parameter) 
for the surviving patients for whom Pneumocystis Jirovecii was cultured, was shorter 
for treatment group A (broad spectrum) than for treatment group B (pathogen-
directed). 
 
For objective three, there was a difference in patient outcome between the two 
treatment groups. The median duration of antimicrobial treatment (secondary 
outcome parameter) for the surviving patients, for whom Pneumocystis Jirovecii was 
cultured, was shorter for treatment group A (broad spectrum) than for treatment 
group B (pathogen-directed).  
52 
 
The treatment that resulted in a higher survival rate (main outcome parameter), 
shorter length of ICU stay and duration of antimicrobial treatment (secondary 
outcome parameters), was the treatment with the better patient outcomes according 
to the outcome parameters set for this study. Thus, for the cultures “revealed” 
analysis, the broad spectrum approach resulted in better patient outcomes than the 
pathogen-directed approach. This analysis was done for patients for whom 
Pneumocystis jirovecii was the only cultured organism. The results for this analysis 
highlights the possibility of co-infection with atypical pathogens and the importance 
of appropriate antimicrobial cover on patient outcome (File, 2015).  
 
The results for the cultures “revealed” analysis were thus the opposite of what 
were found for the culture “blind” analysis. Sample size was small (especially for 
the cultures “revealed” analysis) and could be a reason for the contradicting results. 
A larger study is thus necessary in order to make a valid conclusion. 
 
Objective 4:  
 
The fourth objective of this study was to formulate a set of in-house guidelines 
regarding antimicrobial treatment of ARDS in AIDS patients admitted to the medical 
ICU based on study results. 
 
According to the results for the culture “blind” analysis the pathogen-directed 
approach resulted in better patient outcomes according to the outcome parameters 
set for this study. The pathogen-directed antimicrobial treatment was directed at the 
most common causative pathogens of ARDS; Pneumocystis jirovecii and 











Table 5.1 Treatment B. 
 
Pathogen-directed antimicrobial treatment 
 
Beta-lactam¹ antibiotic + Macrolide/Fluoroquinolone² + Antifungal³ + 
Aminoglycoside + Suxamethonium-Trimethoprim + Anti-viral 
 
¹Ceftriaxone (3rd generation cephalosporin) or Amoxycillin+clavulanic acid/Piperacillin+ tazobactam (beta-lactamase resistant penicillins). 
²Levofloxacin or Moxifloxacin 
 
According to the results of the cultures “revealed” analysis the broad-spectrum 
antimicrobial treatment showed better patient outcomes according to the outcome 
parameters set for this study. This analysis was done for patients for whom 
Pneumocystis jirovecii was the only cultured organism. The broad spectrum 
antimicrobial treatment was directed at both typical and atypical causative 
pathogens of ARDS in HIV infected individuals. See table 5.2 below. 
 
Table 5.2 Treatment A. 
 
Broad spectrum antimicrobial treatment 
 
Beta-lactam antibiotic + Macrolide/Fluoroquinolone + Antifungal + 
Aminoglycoside + Suxamethonium-Trimethoprim + Anti-viral 
 
¹Ceftriaxone (3rd generation cephalosporin) or Amoxycillin+clavulanic acid/Piperacillin+ tazobactam (beta-lactamase resistant penicillins). 
²Levofloxacin or Moxifloxacin 
 
Identifying the most appropriate antimicrobial treatment strategy was necessary in 
order to both ensure optimal clinical outcomes for the AIDS patient with ARDS in 
the ICU and limit emergence of antimicrobial resistance. For this study, the 
pathogen-directed treatment resulted in better patient outcomes for the culture 
“blind” analysis. This approach also theoretically reduces the risk of antimicrobial 
resistance as opposed to the broad spectrum approach (van der Eeden et al., 2005). 
The pathogen-directed antimicrobial approach will therefore be presented in 2016, 
in the form of a draft in-house treatment guideline, as a recommended antimicrobial 
54 
 
treatment approach, to the Drug and Therapeutics committee of the study site 
hospital for treating ARDS among AIDS patients in the ICU. 
 
The results of the cultures “revealed” analysis will also be shared with this 
committee. The results of this analysis were the opposite of what were found for the 
culture “blind” analysis. A possible explanation for the contradicting results between 
the two analyses is small sample size (especially the cultures “revealed” analysis). 
The importance of and need for a larger study for confirmation of the analyses’ 































Globally, HIV prevalence is highest in Sub-Saharan Africa (WHO, 2015). Acute 
respiratory failure is the leading cause for admission and mortality in the ICU for HIV 
infected patients (Sarkar and Rasheed, 2013). There appear to be no formal or 
standardized antimicrobial treatment guidelines for treating ARDS in patients with 
AIDS. Identifying the most appropriate antimicrobial treatment strategy was 
necessary in order to both ensure optimal clinical outcomes for the AIDS patient 
with ARDS in the ICU and limit emergence of antimicrobial resistance. 
 
Data analysis for the first three objectives of the study was done in two ways:  
1) culture “blind” and 2) cultures “revealed”. For the culture “blind” analysis, the 
outcome parameters were compared between the two treatment groups based on 
an approach where antimicrobial therapy is initiated empirically (thus, before culture 
results are known) and that the physicians do not de-escalate broad spectrum 
antimicrobial treatment after culture results for a variety of reasons (Khasawneh et 
al., 2014). For the cultures “revealed” analysis, outcomes were compared between 
the two treatment groups for patients with the same culture result, namely 
Pneumocystis jirovecii. 
 
For the culture “blind” analysis, treatment B (pathogen-directed) showed better 
patient outcomes than treatment A (broad spectrum) for both the main and 
secondary outcome parameters. For the cultures “revealed” analysis, treatment A 
(broad spectrum) showed better patient outcomes than treatment B (pathogen-
directed) for both the main and secondary outcome parameters. Sample size was 
small for this study (especially for the cultures “revealed” analysis) and this could be 
the reason for the contradicting results. 
 
The findings of this study as well as a draft in-house treatment guideline will be 
presented in 2016 to the Drug and Therapeutics committee of the hospital at which 
this study was conducted. The pathogen-directed approach will be the 
recommended treatment approach for treating ARDS among AIDS patients in the 
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ICU for the draft in-house guideline. This approach resulted in better patient 
outcomes for the culture “blind” analysis. It is also the approach that theoretically 
limits the risk of antimicrobial resistance (van der Eeden et al., 2005). However, a 
larger study is necessary in order to confirm these results. 
          
6.2 SIGNIFICANCE OF THE STUDY 
 
Acute respiratory failure is the main cause for admission and mortality in the ICU for 
HIV infected patients (Sarkar and Rasheed, 2013). There appear to be no formal or 
standardized treatment guidelines for the antimicrobial treatment of the underlying 
causative pathogens of this condition. Antimicrobial resistance is a pressing 
international concern (World Health Organization, 2013). The problem with 
antimicrobial resistance is that it reduces effectiveness of treatment. This leads to 
an increase in mortality rate, duration of treatment, healthcare costs and economic 
burden as more expensive therapies have to be used due to resistance to first-line 
treatment. This study represents the first step in identifying the most appropriate 
antimicrobial treatment strategy in order to both ensure optimal clinical outcomes 
for the AIDS patient with ARDS in the ICU and limit emergence of antimicrobial 
resistance.   
 
6.3 STUDY LIMITATIONS 
 
The small sample size was a limitation for this study. Small sample size lowers 
statistical power i.e. the probability of accepting a false null hypothesis; and the 
results may not be reliable (Verial, 2015). In this study, the sample size for the 
cultures “revealed” analysis was too small to perform any formal statistical tests or 




A much larger study of this nature is recommended in order to confirm this study’s 
results. The choice of the significance level (alpha) at 0.05 or less and the use of 
appropriate statistical test(s) is important in order to ensure reliability. The 
effectiveness of the outcomes of the tests i.e. not only the conclusion (reject or 
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accept at specified level alpha), but the size of the difference that the intervention 
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Tool 1 Screening of admission records. 
 
SCREENING OF THE MEDICAL ICU’S ADMISSION RECORDS: 
Indicate Yes or No for each of the criteria. 
Answer should be Yes for all criteria to 
be considered for the study 
        





18 and 65 
Considered 
for the study 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     



















Inclusion Criteria (indicate Yes or No for each of the criteria) Exclusion Criteria (indicate Yes or No for each of the criteria) Included 
(Yes or 
No) 
    
Answer should be Yes for all criteria to be included in the 
study 
 Answer should be No for all criteria to be included in the study 


























             
             
             
             
             
             
             
             
             
             
             
             
             
             

















Tool 3 Treatment group allocation. 
 
Record number of 
patient that meets 
inclusion and 
exclusion criteria 
Antimicrobial treatment received Treatment A (tick this 




Treatment B (tick 
this column if 
patient is allocated 
to “Treatment B 
received” group) 
(Specify the antimicrobials received) 
    
    
    
    
    
    
    


























Tool 4 Treatment group participant’s characteristics. 
 
 
TREATMENT GROUP A: PARTICIPANT’S CHARACTERISTICS 
 
Record no. of 
patient 
Any co-morbidities not listed 
under  exclusion criteria 
(answer Yes or No and 
specify) 
Smoking status Age Sex 
     
     
     
     
     
     
     
     
 
TREATMENT GROUP B: PARTICIPANT’S CHARACTERISTICS: 
 
Record  no. of 
patient 
Any co-morbidities not listed 
under  exclusion criteria 
(answer Yes or No and 
specify) 
Smoking status Age Sex 
     
     
     
     
     
     












Tool 5 Culture results. 
 
 
TREATMENT GROUP A: 




















,No or Not 
applicable) 
(If there were no 
growth, write “no 
growth.”) 
      
      
      
      
      
      
 
TREATMENT GROUP B: 


















(answer Yes or 
No) 
Yes or No (If there were no 
growth, write “no 
growth.”) 
      
      
      
      
      














Tool 6 Main and secondary outcome parameters. 
 
 
TREATMENT GROUP A: 
Record no.. of 
patient 
Did the patient survive 
until ICU discharge? 
(answer Yes or No) 
What was the total 
duration of stay in the 
ICU? (in days) 
What was the total 
duration of 
antimicrobial 
treatment in the ICU? 
(in days) 
    
    
    
    
    
    
    
    
    
    
    
    
TREATMENT GROUP B: 
 
Record no.. of 
patient 
Did the patient survive 
until ICU discharge? 
(answer Yes or No) 
What was the total 
duration of stay in the 
ICU? (in days) 
What was the total 
duration of 
antimicrobial 
treatment in the ICU? 
(in days) 
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1. Clinical setting: 
 
This guideline is recommended for antimicrobial treatment of ARDS among AIDS 
patients in the medical ICU (intensive care unit) of a general private hospital in 
Richards Bay, Kwazulu-Natal North Coast. 
 
2. Rationale for this guideline:  
 
Globally, HIV prevalence is highest in Sub-Saharan Africa (WHO, 2015). Acute 
respiratory failure is the main cause for admission and mortality in the ICU for HIV 
infected patients (Sarkar and Rasheed, 2013). There is an urgent need to examine 
appropriate antimicrobial strategies for treating ARDS in patients with AIDS as there 
appear to be no formal or standardized treatment guidelines. Empirical antimicrobial 
treatment for critically ill ICU patients ranges from a pathogen-directed to a broad 
spectrum approach (Leekha et al., 2010). The concern with a pathogen-directed 
approach is the possibility of undertreating the patient (File, 2015). In contrast, the 
anticipated complication associated with a broad spectrum approach is the potential 
contribution to the emergence of antimicrobial resistance (Leone and Martin, 2008).  
Antimicrobial resistance is as much a problem in South Africa as it is globally and 
can largely affect clinical outcome for patients (Mendelson, 2012). Identifying the 
most appropriate antimicrobial treatment strategy was necessary in order 
recommend an in-house treatment guideline that would ensure optimal clinical 
outcomes for the AIDS patient with ARDS in the ICU and limit emergence of 
antimicrobial resistance.   
 
3. Strength of the recommendation: 
 
Retrospective comparative therapeutic studies, investigating the results of 
treatment, are considered level three evidence according to the Levels of Evidence 
chart by De Vries and Berlet (2010). This study was a retrospective comparative 
study and therefor it was graded as level three evidence. The study was started after 
treatment was completed and participants were identified for the study based on the 




4. Recommended antimicrobial treatment: 
 
Based on this hospital’s microbial test results and the results of the study “A 
Retrospective Comparison of Broad Spectrum and Pathogen-Directed Antimicrobial 
Treatment of Acute Respiratory Distress Syndrome in HIV/AIDS patients” that was 
performed at this hospital by Basson (2016), the following pathogen-directed 
antimicrobial treatment is recommended for the treatment of ARDS among AIDS 
patients in the ICU: 
 
Table 4.1 Pathogen-directed antimicrobial treatment. 
 
Pathogen-directed antimicrobial treatment 
 
Beta-lactam antibiotic + Macrolide/fluoroquinolone + Suxamethonium-
Trimethoprim 
 
Ceftriaxone (3rd generation cephalosporin) or Amoxycillin+clavulanic acid/Piperacillin+ tazobactam (beta-lactamase resistant penicillins). 
²Levofloxacin or Moxifloxacin 
 
The above treatment is aimed at the two most common causative pathogens of 
ARDS in HIV-infected patients, Pneumocystis jirovecii and Streptococcus 
pneumonia (Benito et al, 2012). This treatment (pathogen-directed) resulted in 
better patient outcomes than the broad spectrum approach for the culture “blind” 
analysis of the performed study (Basson, 2016). This pathogen-directed approach 
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